[
  {
    "ts": null,
    "headline": "Doximity Declines 4.4% in a Month: How to Play the Stock Now?",
    "summary": "DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?",
    "url": "https://finnhub.io/api/news?id=372a906eb11710a52d00c5ae440002fb13256e8b266b9ba951b5394675d4e260",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749138240,
      "headline": "Doximity Declines 4.4% in a Month: How to Play the Stock Now?",
      "id": 135064173,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IQV",
      "source": "Yahoo",
      "summary": "DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?",
      "url": "https://finnhub.io/api/news?id=372a906eb11710a52d00c5ae440002fb13256e8b266b9ba951b5394675d4e260"
    }
  },
  {
    "ts": null,
    "headline": "Veeva Systems: AI And Vault CRM Are Key Long-Term Tailwinds",
    "summary": "Veeva Systems' strong Q1 FY2026 results highlight AI innovation and industry expertise. Click to read my full analysis of the VEEV stock.",
    "url": "https://finnhub.io/api/news?id=a3bab8041937e04facb516d69fda6528043ce36c1f0c83ab3865b3f629a2233b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749114900,
      "headline": "Veeva Systems: AI And Vault CRM Are Key Long-Term Tailwinds",
      "id": 135045813,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149749988/image_2149749988.jpg?io=getty-c-w1536",
      "related": "IQV",
      "source": "SeekingAlpha",
      "summary": "Veeva Systems' strong Q1 FY2026 results highlight AI innovation and industry expertise. Click to read my full analysis of the VEEV stock.",
      "url": "https://finnhub.io/api/news?id=a3bab8041937e04facb516d69fda6528043ce36c1f0c83ab3865b3f629a2233b"
    }
  },
  {
    "ts": null,
    "headline": "Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks",
    "summary": "Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season.",
    "url": "https://finnhub.io/api/news?id=02ce2fbd339785d78ff47ccfa409d8f518ca83029324509ea7d6936ef9a1126b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749094584,
      "headline": "Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks",
      "id": 135045289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IQV",
      "source": "Yahoo",
      "summary": "Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season.",
      "url": "https://finnhub.io/api/news?id=02ce2fbd339785d78ff47ccfa409d8f518ca83029324509ea7d6936ef9a1126b"
    }
  }
]